# US 9,872,840 B2 · Effect of garcinol in delaying the progression of diabetic nephropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,840 B2
- Document ID: US9872840B2
- Status: Granted
- Kind: B2
- Application number: 15/027,200
- Filed: 2013-10-03
- Published: 2016-08-18
- Granted: 2018-01-23
- Earliest claimed: 2013-10-03
- Assignees: Delhi Institute of Pharmaceutical Sciences and Research
- Applicants: Delhi Institute of Pharmaceutical Sciences and Research
- Inventors: Sonia Gandhi; B. P. Srinivasan
- Web page: https://patentgrep.com/patent/US9872840B2

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 36/38: Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
- C07C 49/623: having two rings
- C07C 49/703: containing hydroxy groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to the use of garcinol as a nephroprotective agent. The present invention also relates to the use of garcinol as a therapeutic agent in renal disorders, in particular diabetic nephropathy, and to medicinal preparations containing garcinol. Further disclosed herein are method of treatment of renal disorders, in particular diabetic nephropathy by administration of garcinol.

## Claims

### Claim 1

A method of providing Garcinol to a subject that has diabetic nephropathy comprising:
selecting a subject that has diabetic nephropathy; and
providing said subject an amount of Garcinol in the range of 100 mg/kg to 1000 mg/kg bodyweight of said subject, thereby inhibiting progression of diabetic nephropathy in the subject.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the amount of Garcinol provided to said subject is about 200 mg/kg/day.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein Garcinol is provided orally or by injection.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the rate of increase of serum creatinine is lowered in said subject.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein albuminuria is stabilized in said subject.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the plasma protein levels, erythopoeitin levels, and/or adiponectin levels is increased in said subject.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the expression of nephrin is increased in said subject.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein the rate of increase of cystatin c is increased in said subject, and the amount of B2M is decreased in said subject.

### Claim 9 (depends on 1)

The method as claimed in claim 1, wherein glomerulosclerosis is reduced in said subject.

### Claim 10

The method as claimed in 1, wherein the amount of nitric oxide is reduced in said subject.

### Claim 11 (depends on 1)

The method as claimed in claim 1, wherein apoptosis is reduced in said subject.

### Claim 12 (depends on 1)

The method as claimed in claim 1, wherein the expression of desmin is decreased in said subject.